| Data | Hora | Fonte | Título | Código | Companhia |
| 26/12/2018 | 11:01 | Edgar (US Regulatory) | Termination of Registration of a Class of Security Under Section 12(g) (15-12g) | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |
| 26/12/2018 | 09:02 | Edgar (US Regulatory) | Notice of Effectiveness (effect) | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |
| 13/12/2018 | 19:42 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |
| 13/12/2018 | 18:54 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |
| 13/12/2018 | 12:20 | Edgar (US Regulatory) | Post-effective Amendment to Proposed Securities Act Rule 462(b) Registration Statement (pos462b) | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |
| 13/12/2018 | 12:09 | Edgar (US Regulatory) | Post-effective Amendment to an Automatic Shelf Registration of Form S-3asr or Form F-3asr (posasr) | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |
| 13/12/2018 | 11:25 | Edgar (US Regulatory) | Post-effective Amendment to Registration Statement (pos Am) | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |
| 13/12/2018 | 10:49 | Edgar (US Regulatory) | Post-effective Amendment to an S-8 Filing (s-8 Pos) | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |
| 13/12/2018 | 10:21 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |
| 12/12/2018 | 19:42 | Edgar (US Regulatory) | Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ... | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |
| 11/12/2018 | 15:00 | GlobeNewswire Inc. | Keryx Biopharmaceuticals Stockholders Approve Merger with Akebia Therapeutics | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |
| 03/12/2018 | 19:09 | Edgar (US Regulatory) | Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |
| 30/11/2018 | 11:55 | GlobeNewswire Inc. | Glass Lewis Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics... | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |
| 29/11/2018 | 10:00 | GlobeNewswire Inc. | ISS Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |
| 15/11/2018 | 20:15 | Business Wire | Akebia Therapeutics and Keryx Biopharmaceuticals Announce Chairperson for Combined Company | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |
| 13/11/2018 | 09:07 | Edgar (US Regulatory) | Amended Quarterly Report (10-q/a) | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |
| 08/11/2018 | 19:30 | GlobeNewswire Inc. | Keryx Biopharmaceuticals Announces Third Quarter 2018 Financial Results | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |
| 06/11/2018 | 19:30 | GlobeNewswire Inc. | Keryx Biopharmaceuticals to Release Third Quarter 2018 Financial Results on Thursday, November 8, 2018 | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |
| 30/10/2018 | 18:31 | GlobeNewswire Inc. | Keryx Biopharmaceuticals Announces Filing of Definitive Joint Proxy Statement in Connection with Pending Merger with Akebia T... | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |
| 30/10/2018 | 18:28 | Edgar (US Regulatory) | Proxy Statement - Merger or Acquistion (definitive) (defm14a) | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |
| 01/10/2018 | 10:16 | GlobeNewswire Inc. | Keryx Biopharmaceuticals Announces Participation in an Upcoming Investor Conference | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |
| 24/09/2018 | 16:31 | Edgar (US Regulatory) | Confidential Treatment Order (ct Order) | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |
| 09/08/2018 | 17:21 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |
| 08/08/2018 | 08:00 | GlobeNewswire Inc. | Keryx Biopharmaceuticals Announces Second Quarter 2018 Financial Results | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |
| 02/08/2018 | 17:05 | GlobeNewswire Inc. | Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2018 Financial Results on Wednesday, August 8, 2018 | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |
| 29/06/2018 | 20:12 | PR Newswire (US) | WeissLaw LLP Investigates Keryx Biopharmaceuticals Inc. | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |
| 29/06/2018 | 17:29 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (s-8) | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |
| 28/06/2018 | 08:00 | Business Wire | Akebia Therapeutics & Keryx Biopharmaceuticals to Merge, Creating a Fully Integrated Company Focused on the Development & Com... | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |
| 20/06/2018 | 10:21 | GlobeNewswire Inc. | Keryx Biopharmaceuticals Announces Participation in a Renal Disease Panel at the JMP Securities Life Sciences Conference on T... | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |
| 31/05/2018 | 17:14 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) | NASDAQ:KERX | Keryx Biopharmaceuticals, Inc. (delisted) |